<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885482</url>
  </required_header>
  <id_info>
    <org_study_id>2009−011273−32</org_study_id>
    <nct_id>NCT00885482</nct_id>
  </id_info>
  <brief_title>Atazanavir and Lamivudine for Treatment Simplification</brief_title>
  <acronym>AtLaS</acronym>
  <official_title>Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Atazanavir/Ritonavir + Lamivudine in Patients Stably Treated With Two NRTIs + Atazanavir/Ritonavir With Optimal Virologic Response.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives of the study:

        1. To verify the safety of the study treatment, defined as the persistent control of the
           virus' replication at 48 weeks after the simplification to lamivudine + atazanavir with
           ritonavir.

        2. To collect relevant information about the safety and the metabolic impact of this
           strategy in order to eventually design a non-inferiority randomized controlled trial for
           the evaluation of the safety and the efficacy of this strategy in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combined antiretroviral therapy has greatly improved the natural history of HIV
      infection/AIDS. Yet, it is associated with important short- and long- term side effects. In
      particular, nucleoside and nucleotide analogs may cause anemia, pancreatitis, mitochondrial
      dysfunction, lactic acidosis, lipoatrophy and reduction of renal function or of bone density.

      Our study aims to verify the safety and efficacy of a simplification of a dual therapy
      (Lamivudine plus Atazanavir with Ritonavir), confiding on the potency and high genetic
      barrier of ritonavir-boosted agents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Virological Failure (Two Consecutive Measures of HIV-RNA Higher Than 50 Copies/mL or a Single Measure Higher Than 1000 Copies/mL) Within 48 Weeks at intention-to.Treat Analysis</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Virological Failure at Survival Analysis</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Viral Load Lower Than 50 Copies/mL at 48 Weeks at the Intention to Treat Analysis</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of CD4 Cell Count During the 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Adherence and Quality of Life During the 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Atazanavir Plasma Concentrations During the 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Metabolic Parameters at 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the Results of Neurocognitive Tests at 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Bone Density and of Subcutaneous Fat at 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment simplification from a &quot;standard&quot; combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamiduvine (Epivir)</intervention_name>
    <description>Epivir 300 mg</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir (Reyataz)</intervention_name>
    <description>Reyataz 300 mg</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir (Norvir)</intervention_name>
    <description>Norvir 100 mg</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated with the same regimen including 2NRTIs + ATV/r from at least 6 months

          -  Aged 18 years or older

          -  Who gave informed consent to the participation to the study

          -  With at least two viral load &lt; 50 copies/mL in two consecutive determinations at least
             3 months apart

          -  With CD4 cell count &gt; 200 cells/μL and absence of any opportunistic infection or
             AIDS-related disease by one year at least

        Exclusion Criteria:

          -  Pregnancy or breast feeding, desire of pregnancy in the short term

          -  Previous virological failure to antiretroviral therapy and/or previous exposure to
             mono- or dual therapies with reverse transcriptase nucleosidic analogues

          -  Patients with insufficient atazanavir plasma through concentration (lower than 0.23
             μg/mL at 12th hour or 0.15 μg/mL at 24th hour) at screening and/or at baseline

          -  Patients with grade 3 or 4 laboratory abnormalities at screening (except for glucose
             or lipid serum levels and direct or indirect bilirubin)

          -  Concomitant treatment with antacids or proton-pump blockers or any other drug with
             known interactions or contraindications with the study medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea De Luca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of Sacred Heart</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <results_first_submitted>February 4, 2015</results_first_submitted>
  <results_first_submitted_qc>February 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2015</results_first_posted>
  <last_update_submitted>February 23, 2015</last_update_submitted>
  <last_update_submitted_qc>February 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Andrea De Luca</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV/AIDS</keyword>
  <keyword>HAART</keyword>
  <keyword>Simplification</keyword>
  <keyword>Atazanavir</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm</title>
          <description>Treatment simplification from a &quot;standard&quot; combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>low Therapeutic drug monitoring (TDM)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>Treatment simplification from a &quot;standard&quot; combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Virological Failure (Two Consecutive Measures of HIV-RNA Higher Than 50 Copies/mL or a Single Measure Higher Than 1000 Copies/mL) Within 48 Weeks at intention-to.Treat Analysis</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Treatment simplification from a &quot;standard&quot; combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Virological Failure (Two Consecutive Measures of HIV-RNA Higher Than 50 Copies/mL or a Single Measure Higher Than 1000 Copies/mL) Within 48 Weeks at intention-to.Treat Analysis</title>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Virological Failure at Survival Analysis</title>
        <time_frame>48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Viral Load Lower Than 50 Copies/mL at 48 Weeks at the Intention to Treat Analysis</title>
        <time_frame>48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evolution of CD4 Cell Count During the 48 Weeks</title>
        <time_frame>48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evolution of Adherence and Quality of Life During the 48 Weeks</title>
        <time_frame>48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evolution of Atazanavir Plasma Concentrations During the 48 Weeks</title>
        <time_frame>48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Metabolic Parameters at 48 Weeks</title>
        <time_frame>48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of the Results of Neurocognitive Tests at 48 Weeks</title>
        <time_frame>48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Bone Density and of Subcutaneous Fat at 48 Weeks</title>
        <time_frame>48 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>Treatment simplification from a &quot;standard&quot; combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>brain hemorrage and subsequent myocardial infarction</sub_title>
                <description>Brain hemorrage ans subsequent death for myocardial infarction in a 63 years old female, with a previous history of head trauma and hypertension; events not judged as drug-related since they happened in a high-risk patient</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal colics</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrea De Luca</name_or_title>
      <organization>Catholic University of S. Heart</organization>
      <phone>+390630155366</phone>
      <email>deluca.andrea@fastwebnet.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

